Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Michał Gil"'
Autor:
Michał Gil, Magdalena Knetki-Wróblewska, Przemysław Niziński, Maciej Strzemski, Paweł Krawczyk
Publikováno v:
Annals of Medicine, Vol 55, Iss 1, Pp 1018-1028 (2023)
AbstractMetastases to the central nervous system (CNS) in patients with non-small cell lung cancer constitute an extremely difficult clinical problem, and their occurrence is associated with a poor prognosis. Due to the existence of the blood-brain b
Externí odkaz:
https://doaj.org/article/d944926d500c4a3c80977ba12df8b70e
Autor:
Anna K. Rekowska, Piotr Rola, Agnieszka Kwiatkowska, Magdalena Wójcik-Superczyńska, Michał Gil, Paweł Krawczyk, Janusz Milanowski
Publikováno v:
Biomedicines, Vol 12, Iss 2, p 325 (2024)
Mutations in the KRAS gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two KRAS inhibitors, sotorasib and adagrasib, have recently been approved for the t
Externí odkaz:
https://doaj.org/article/05ffdb3edf2a4b11b59be44081022dac
Autor:
Paweł Krawczyk, Anna Grenda, Paulina Terlecka, Justyna Błach, Kamila Wojas-Krawczyk, Tomasz Kucharczyk, Izabela Chmielewska, Robert Kieszko, Bożena Jarosz, Michał Gil, Katarzyna Reszka, Janusz Milanowski
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract In patients with advanced non-small cell lung cancer (NSCLC), comprehensive genetic diagnostics is currently carried out in order to qualify for molecularly targeted therapies and immunotherapy. The aim of the study was to assess the usefuln
Externí odkaz:
https://doaj.org/article/0b0280e474be480fb01bad2628801426
Autor:
Michał Gil, Izabela Chmielewska, Paweł Krawczyk, Przemysław Niziński, Maciej Strzemski, Janusz Milanowski
Publikováno v:
Oncology in Clinical Practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7aa36760b27694300aecf5d0fc9149d
https://doi.org/10.5603/ocp.2023.0011
https://doi.org/10.5603/ocp.2023.0011
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michał Gil, Magdalena Słomiany-Szwarc, Anna Grenda, Ewelina Iwan, Bożena Jarosz, Paweł Krawczyk, Dariusz Wasyl, Arkadiusz Bomba, Izabela Chmielewska, Tomasz Kucharczyk, Kamila Wojas-Krawczyk, Janusz Milanowski, Katarzyna Reszka
Publikováno v:
Oncology in Clinical Practice. 16:364-368
Anti-PD-1 or PD-L1 immunotherapy in some patients with non-small cell lung cancer (NSCLC) may not be effective, despite the high percentage of cancer cells with PD-L1 expression (≥ 50%). TMB (tumor mutation burden), smoking status and low intestina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::815b6f6c85326de8d2d7febfa88c77bb
https://doi.org/10.5603/ocp.2020.0031
https://doi.org/10.5603/ocp.2020.0031
Autor:
Tomasz Kucharczyk, Natalia Krzyżanowska, Michał Gil, Irena Wieleba, Kamila Wojas-Krawczyk, Paweł Krawczyk, Janusz Milanowski, Iwona Paśnik
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 9133, p 9133 (2021)
International Journal of Molecular Sciences, Vol 22, Iss 9133, p 9133 (2021)
The efficiency of immunotherapy using monoclonal antibodies that inhibit immune checkpoints has been proven in many clinical studies and well documented by numerous registration approaches. To date, PD-L1 expression on tumor and immune cells, tumor m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bea2ac915734fce10a1f381ec4df3c
https://pubmed.ncbi.nlm.nih.gov/34502043
https://pubmed.ncbi.nlm.nih.gov/34502043
Publikováno v:
Cancers, Vol 13, Iss 2836, p 2836 (2021)
Cancers
Cancers
Simple Summary Here, we focused on the most important mechanisms of action of combined immunotherapy with modern anticancer approaches in patients with non-small-cell lung cancer. This knowledge is extremely important for lung cancer clinicians. Firs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f285663dc7f669f854a52efe4c07bf2d
https://www.mdpi.com/2072-6694/13/11/2836
https://www.mdpi.com/2072-6694/13/11/2836
Autor:
Kinga Lew, Paweł Krawczyk, Aleksandra Szczesna, Andrzej Sieracki, Kinga Krukowska, Tomasz Kucharczyk, Bożena Jarosz, Rodryg Ramlau, Robert Kieszko, Andrzej Kazarnowicz, Jan Siwiec, Justyna Błach, Daria Świniuch, Piotr Serwatowski, Tomasz Grodzki, Sebastian Fidler, Iwona Paśnik, Janusz Milanowski, Izabela Chmielewska, Katarzyna Stencel, Aleksandra Bożyk, Michał Gil, Jarosław Buczkowski, Katarzyna Reszka, Tomasz Kubiatowski, Juliusz Pankowski, Anna Grenda
Publikováno v:
Oncology Letters
Anti-programmed death-1 or anti-programmed death-ligand 1 (PD-L1) blockade may be ineffective in some patients with non-small cell lung cancer (NSCLC) with high percentage of tumor cells with PD-L1 expression. In addition, immunotherapy may provide g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842c1dc8a3127125c6eb33823ccfd1d1
https://pubmed.ncbi.nlm.nih.gov/33868487
https://pubmed.ncbi.nlm.nih.gov/33868487